Britte Kranenburg

A phase 2 multicentre study of siltuximab, an anti‐interleukin‐6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

Peter M. Voorhees, Robert Manges, Pieter Sonneveld et al. · British Journal of Haematology · 2013 · 143 citations

Pharmacy, Immunology, Pharmacotherapy +17

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma

Timothy Brighton, Amit Khot, Simon J. Harrison et al. · Clinical Cancer Research · 2019 · 70 citations

Medicine, Immunology, Pharmacotherapy +17

Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy

Michael Wang, André Goy, Peter Martin et al. · Blood · 2014 · 34 citations

Medicine, Hematology, Oncology +10

Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Sriram Balasubramanian, Michael Schäffer, William Deraedt et al. · Blood · 2014 · 31 citations

Medicine, Oncology, Pharmacotherapy +17

A phase 2, randomized, double‐blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low‐ or intermediate‐1–risk myelodysplastic syndrome

Guillermo Garcia‐Manero, Gary Gartenberg, David P. Steensma et al. · American Journal of Hematology · 2014 · 23 citations · Full text

Medicine, Hematology, Immunology +12